Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Medulloblastoma is a frequent and aggressive childhood brain tumor.
• Improved therapeutic strategies are crucial for better patient outcomes.
• PRAME is a tumor-associated antigen with potential as a therapeutic target.

Purpose of the Study:

• To evaluate PRAME expression in medulloblastoma.
• To assess the efficacy of PRAME-specific T cell receptor (TCR) T cells for medulloblastoma immunotherapy.
• To incorporate a safety switch for genetically modified T cells.

Main Methods:

• PRAME expression analysis in 60 medulloblastoma patient biopsies.
• In vitro killing assays using PRAME-specific TCR T cells against medulloblastoma cell lines.
• In vivo studies using an orthotopic mouse model.
• Introduction of an inducible caspase-9 (iC9) safety switch.

Main Results:

• PRAME was detected in 82% of medulloblastoma tissues, irrespective of subgroup.
• High PRAME expression correlated with poorer overall survival.
• PRAME-specific TCR T cells demonstrated efficient killing of medulloblastoma cells and controlled tumor growth in mice.
• The iC9 safety switch enabled prompt elimination of T cells.

Conclusions:

• PRAME is a viable therapeutic target for medulloblastoma.
• Genetically modified T cells with PRAME-specific TCRs offer a promising immunotherapy approach.
• The iC9 safety switch enhances the safety profile of engineered T cell therapies for medulloblastoma.